Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Flexion's OA Knee Injection On Track For H2 Filing

This article was originally published in Scrip

Executive Summary

Burlington, Mass.-based Flexion Therapeutics Inc.'s long-acting steroid injection Zilretta has been associated with statistically significant improvements in pain relief in a pivotal Phase III study in patients with knee osteoarthritis, countering disappointing results from a Phase IIb study reported last year and keeping the product in line for a US NDA submission in the second half on 2016.

You may also be interested in...



Flexion's Zilretta Poised For Market Of Diabetics With Knee Pain

FDA labeling in knee pain osteoarthritis is favorable for long-acting steroid Zilretta and a sales force is lined up, but Flexion has its commercial work cut out competing with very cheap generics.

Keeping Track: Flexion's Non-Opioid Knee Pain Drug Gets OK, Botox Gets Another Approval

The latest drug development news and highlights from our Performance Tracker.

Flexion CEO Makes The Case For Zilretta

Flexion CEO Mike Clayman shares expectations for Zilretta for knee osteoarthritis and discusses plans for commercialization in an interview at the Biotech Showcase in January.

Related Content

Topics

UsernamePublicRestriction

Register

OM005224

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel